Therapeutic targeting of the immune system in cancer is now a clinical reality and marked
successes have been achieved, most notably through the use of checkpoint blockade …

Pancreatic cancer is a deadly disease with high mortality due to difficulties in its early
diagnosis and metastasis. The tumor microenvironment induced by interactions between …

Cyclic dinucleotide (CDN) agonists of stimulator of interferon genes (STING) are a promising
class of immunotherapeutics that activate innate immunity to increase tumour …

Tumor-draining lymph node (TDLN) invasion by metastatic cells in breast cancer correlates
with poor prognosis and is associated with local immunosuppression, which can be partly …

Cancer immunotherapy and vaccine development have significantly improved the fight
against cancers. Despite these advancements, challenges remain, particularly in the clinical …

The nature of the anti-tumor immune response changes as primary tumors progress and
metastasize. We investigated the role of resident memory (Trm) and circulating memory …

Strategies of improving vaccine targeting ability toward lymph nodes have been attracting
considerable interest in recent years, though there are remaining delivery barriers based on …

Anti-CTLA-4 antibodies have successfully elicited durable tumor regression in the clinic;
however, long-term benefit is limited to a subset of patients for select cancer indications. The …

The design of nanovaccines capable of triggering effective antitumor immunity requires an
understanding of how the immune system senses and responds to threats, including …

Although systemic immunotherapy has achieved durable responses and improved survival
for certain patients and cancer types, low response rates and immune system-related …